<table>
<thead>
<tr>
<th>Name of Individual</th>
<th>Individual's Role(s) in Activity</th>
<th>Name of Commercial Interest(s)</th>
<th>Nature of Relationship(s)</th>
</tr>
</thead>
</table>
| Abazeed, Mohamed         | Faculty                          | 1) Patent Holder on Deep Profiler, an image software tool that predict personalized radiation doses | 1) Patent Holder  
|                          |                                  | 2) Siemens Healthcare                                                                        | 2) Contracted/Supported Research Grant                                                   |
| Agarwal, Charu           | Faculty                          | 1) BMS, Roche, AZ, Merck, Celgene                                                            | 1) Advisory Board                                                                       |
| Antonoff, Mara           | Faculty                          | Nothing to disclose                                                                          | Nothing to disclose                                                                       |
| Argento, Angela Christine| Conference Planner (Chair, Program Committee), Abstract Reviewer | 1) Cook, Olympus, Biosenseis                                                                | 1) Advisory Board  
|                          |                                  | 2) Cook, Olympus, Biosenseis                                                                | 2) Honorarium received from Promotional Activity                                         |
| Babu, Govind             | CME Committee Reviewer           | 1) Eli Lilly, Boeckx, Novartis                                                              | 1) Speakers Bureau                                                                       |
| Bauml, Joshua            | CME Committee Reviewer           | 1) Bristol-Myers Squibb, AstraZeneca, Celgene Corporation, Merck & Co., Janssen, Genentech, 
|                          |                                  | Guardant Health, Boehringer Ingelheim, Takeda Pharmaceutical Company, Ltd., Regeneron Pharmaceuticals | 1) Consultant  
| Beard, Frances           | Faculty                          | Nothing to disclose                                                                          | Nothing to disclose                                                                       |
| Belani, Chandra          | Staff Liaison, Faculty           | 1) Genentech, Takeda                                                                           | 1) Speakers Bureau                                                                       |
| Beutner, Christine       | Faculty                          | 1) AstraZeneca, Genentech, Pfizer                                                           | 1) Advisory Board  
|                          |                                  | 2) Novartis                                                                                 | 2) Speakers Bureau                                                                       |
|                          |                                  | 3) EMD Serono                                                                                | 4) Speakers Bureau (Travel)                                                              |
| Black, Kirsten           | Staff Liaison                    | Nothing to disclose                                                                          | Nothing to disclose                                                                       |
| Bier, Lori               | Staff Liaison                    | Nothing to disclose                                                                          | Nothing to disclose                                                                       |
| Bidor, Joseph            | Faculty                          | Nothing to disclose                                                                          | Nothing to disclose                                                                       |
| Boffa, Daniel            | Faculty                          | Nothing to disclose                                                                          | Nothing to disclose                                                                       |
| Bonomi, Phil             | Faculty                          | 1) Merck, Pfizer, Roche Genentech, AstraZeneca                                              | 1) Advisory Board                                                                       |
| Brahmer, Julia           | Conference Planner (Chair, Program Committee), Faculty, Abstract Reviewer | 1) Eli Lilly, Genentech, BMS, Merck, Amgen                                                  | 1) Advisory Board  
|                          |                                  | 2) BMS                                                                                      | 2) Contracted/Supported Research Grant                                                   |
|                          |                                  | 3) Roche                                                                                    | 3) Honorarium received from promotional activities                                         |
| Bunn, Becky              | Staff Liaison                    | Nothing to disclose                                                                          | Nothing to disclose                                                                       |
| Burt, Bryan              | Faculty                          | 1) Monomento-Gene                                                                            | 1) Contracted/Supported Research Grant                                                   |
|                          |                                  | 2) Bexyou Surgical                                                                          | 2) Founder                                                                               |
| Burt, Bryan              | Conference Planner (Chair, Program Committee), Abstract Reviewer | 1) Monomento-Gene                                                                            | 1) Contracted/Supported Research Grant                                                   |
|                          |                                  | 2) Founder - Bexyou Surgical                                                                 | 2) Other                                                                                 |
| Carbone, David           | Faculty                          | 1) AstraZeneca, EMD Serono/Merck/Genentech                                                   | 1) Advisory Board  
|                          |                                  | 2) Pfizer, BMS                                                                             | 2) Honorarium                                                                            |
|                          |                                  | 3) Genetrix, Gloria Biosciences, Roche, BMS, GIK, Daiichi Sangyo Inc                         | 3) Consultant                                                                            |
| Chimera, Steve           | Faculty                          | 1) Astellas Pharma                                                                          | 1) Employment, Senior Medical Director (Spouse)                                          |
|                          |                                  | 2) Refresh Medical                                                                          | 2) Consultant                                                                            |
| Chimera, Steven          | Conference Planner (Chair, Program Committee), Abstract Reviewer | 1) Reflexion Medical                                                                         | 1) Consultant                                                                            |
|                          |                                  | 2) Astellas Opusue                                                                           | 2) Employment                                                                            |
|                          |                                  | 3) BMS, Merck, EMD                                                                          | 3) Contracted/Supported Research Grant                                                   |
|                          |                                  | 4) UpToDate                                                                                 | 4) Royalties/Intelectual Property/Patent Holder                                           |
| Craig, Sarah             | Faculty                          | Nothing to disclose                                                                          | Nothing to disclose                                                                       |
| Crouse, Melissa          | Faculty                          | Nothing to disclose                                                                          | Nothing to disclose                                                                       |
| Colligan, Melissa        | Conference Planner (Chair, Program Committee), Abstract Reviewer | Nothing to disclose                                                                          | Nothing to disclose                                                                       |
| Cummings, Mike          | Faculty                          | Nothing to disclose                                                                          | Nothing to disclose                                                                       |
| Dagenaudt, Jill          | Staff Liaison                    | Nothing to disclose                                                                          | Nothing to disclose                                                                       |
| Diet, John               | Faculty                          | Nothing to disclose                                                                          | Nothing to disclose                                                                       |
| Dunnington, Jessica      | Conference Planner (Chair, Program Committee), Faculty, Abstract Reviewer | 1) AstraZeneca  
|                          |                                  | 2) AstraZeneca, BMS                                                                         | 1) Speakers Bureau                                                                       |
|                          |                                  | 3) Genentech                                                                                | 2) Advisory Board                                                                       |
|                          |                                  | 4) Siemens Healthcare                                                                       | 3) Consultant                                                                            |
| Doroshowe, Deborah       | Faculty                          | Nothing to disclose                                                                          | Nothing to disclose                                                                       |
| Durm, Greg               | Faculty                          | 1) Merck                                                                                    | 1) Research Grant  
<p>|                          |                                  | 2) AstraZeneca                                                                              | 2) Research Grant                                                                       |
|                          |                                  | 3) BMS                                                                                      | 3) Contracted Support/Research Grant                                                     |
|                          |                                  | 4) AstraZeneca                                                                              | 4) Honorarium received from promotional activities                                         |
| Elkins, Ivy              | Conference Planner (Chair, Program Committee), Abstract Reviewer | 1) BMS, Amgen, AstraZeneca, Boehringer Ingelheim (me)                                      | 1) Consultant                                                                            |
| Elkins, Ivy              | Faculty                          | 1) BMS, Amgen, AstraZeneca, Boehringer Ingelheim (me)                                      | 1) Consultant                                                                            |</p>
<table>
<thead>
<tr>
<th>Name of Individual</th>
<th>Individual's Role(s) in Activity</th>
<th>Name of Commercial Interest(s)</th>
<th>Nature of Relationship(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Els, Talee</td>
<td>Staff Liaison</td>
<td>Nothing to disclose</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Evans, Bill</td>
<td>Faculty</td>
<td>1) Abbvie, AstraZeneca, Axetia, BMS/Calgene Eusa, Gilead, Janssen, Merck</td>
<td>1) Advisory Board</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2) AstraZeneca, Sanofi, Calgene, Janssen, Lilly, Shire, Takeda</td>
<td>2) Consultant</td>
</tr>
<tr>
<td>Fathi, Jassie</td>
<td>Faculty</td>
<td>Nothing to disclose</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Feldman, Jill</td>
<td>Conference Planner (Chair, Program Committee)</td>
<td>Nothing to disclose</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td></td>
<td>Abstract Reviewer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ferrantei, Renata</td>
<td>Faculty</td>
<td>1) Regeneron Sanofi</td>
<td>1) Advisory Board</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2) Bicara</td>
<td>2) Consultant</td>
</tr>
<tr>
<td>Fuller, Mary Jo</td>
<td>Conference Planner (Chair, Program Committee)</td>
<td>1) Merck, Genentech</td>
<td>1) Speakers Bureau</td>
</tr>
<tr>
<td></td>
<td>Abstract Reviewer</td>
<td>2) AstraZeneca</td>
<td>2) Advisory Board</td>
</tr>
<tr>
<td></td>
<td>Faculty</td>
<td>3) Pfizer, Biodesis</td>
<td>3) Contracted/Supported Research Grant</td>
</tr>
<tr>
<td>Forde, Patrick</td>
<td>Conference Planner (Chair, Program Committee)</td>
<td>1) AstraZeneca</td>
<td>1) Advisory Board</td>
</tr>
<tr>
<td></td>
<td>Abstract Reviewer</td>
<td>2) AstraZeneca, BMS, Kyowa, Novartis, Cosus, Kyowa, Array</td>
<td>2) Contracted/Supported Research Grant</td>
</tr>
<tr>
<td></td>
<td>Faculty</td>
<td>3) Abbvie, BMS, AstraZeneca, Janssen</td>
<td>3) Consultant</td>
</tr>
<tr>
<td>Freeman-Daly, Janet</td>
<td>Faculty</td>
<td>1) STAT News</td>
<td>1) Travel Expenses</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2) Turning Point Therapeutics</td>
<td>2) Travel Expenses</td>
</tr>
<tr>
<td>Gainor, Justin</td>
<td>Faculty</td>
<td>1) Bristol-Myers Squibb, Genentech, Ariad/Takeda, Los/Lilly, Blueprint, Oncorpus, Regeneron</td>
<td>1) Consultant</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Gilead, AstraZeneca, Pfizer, Incyte, Novartis, Merck, Agios, Agios, and Array</td>
<td>1) Contracted/Supported research grant</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Novartis, Genentech/Nodeo, and Ariad/Takeda, Bristol-Myers Squibb, Tesaro, Moderna, Blueprint,</td>
<td>1) Other - Employee (Family member)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Jounse, Array Bipharm, Merck, Adaptimmune, Novartis, and Alesio</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>3) Innovo Pharmaceuticals</td>
<td></td>
</tr>
<tr>
<td>Cantu, Apar Kishor</td>
<td>CME Committee Reviewer</td>
<td>1) AstraZeneca, Genentech, G1 Therapeutics, Cardinal Health, Flagship Biosciences</td>
<td>1) Advisory Board</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2) AstraZeneca</td>
<td>2) Consultant</td>
</tr>
<tr>
<td></td>
<td></td>
<td>3) Takeda, Merck, NEKTAR, Apergen, Novartis, AstraZenca</td>
<td>3) Contracted/Support Grant</td>
</tr>
<tr>
<td>Gareseme, Marina</td>
<td>Faculty</td>
<td>1) Chouka Pharma, Incyte, EL Lilly, BMS, Roche, Calgene, Takeda, MSD, AstraZeneca, Takeda,</td>
<td>1) Advisory Board</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Takeda Russia</td>
<td>2) Advisory Board</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2) Boehringer Ingelheim, Novartis, Pfizer, Inivata, Seattle Genetics, Daisich-Sangyo - Incyte,</td>
<td>3) Contracted/Supported Research Grant</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EL Lilly, BMS, Roche, Calgene, MSD, AstraZeneca, Takeda</td>
<td>4) Royalty/Intellectual Property/Patent Holder</td>
</tr>
<tr>
<td></td>
<td></td>
<td>3) MSD, AstraZeneca</td>
<td>5) Institutional financial interests</td>
</tr>
<tr>
<td></td>
<td></td>
<td>4) Merck KGaA - AstraZeneca ABOURITED THERAPEUTICS CORPORATION - F. Hoffmann-</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>La Roche, Ltd-Incyte Corporation - Merck Sharp &amp; Dohme Corporation - Novartis Farma s.p.A.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>TAKEDA Pharmaceuticals -SPECTRUM PHARMACEUTICALS - Exelixis Inc. -</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Silkostrinha s.p.a. advisory role, Steering Committee; research funding:</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Spectrum Pharmaceuticals, Blueprint Medicine</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>5) Patent n°/ Application n° 19185724.2-1111 date: 03/08/2019 Immunotherapy in</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Advanced NGCL</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>6) Local PI, enrollment in clinical trials: BMS, Roche, Tiziana Sciences, Glovo, Merck,</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Serono, AstraZeneca, Calgene, Chouka Pharma, Bayer, Pfizer, MSD, EL Lilly, Novartis Leadership</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>roles: President, Women for Oncology Italy, Member of ESMO task Forces (Publishing Working</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Group, Press Committee, Public Policy, Women For Oncology, Member of ASCO Scientific</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Committee, Board member of AIT (Associazione Italiana Oncologia Toracica), Scientific Committee</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Member (EACR-ESMO, ELC, WCCL, ASCO)</td>
<td></td>
</tr>
<tr>
<td>Gentzler, Ryan</td>
<td>Faculty</td>
<td>1) AstraZeneca</td>
<td>1) Consultant</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2) Pfizer, Merck, Bristol-Myers Squibb, Takeda, Heikin, Jounse</td>
<td>2) Contracted/Supported Research Grant</td>
</tr>
<tr>
<td>Gilbet, Natasha</td>
<td>Staff Liaison</td>
<td>Nothing to disclose</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Gilkespie, Erin</td>
<td>Faculty</td>
<td>Nothing to disclose</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Goros, Daniel</td>
<td>Faculty</td>
<td>1) Varian</td>
<td>1) Taught Class/Honorarium</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2) Olympus</td>
<td>2) Advisory Board</td>
</tr>
<tr>
<td>Gomrez, Maciej</td>
<td>Faculty</td>
<td>Nothing to disclose</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Gray, Justelle</td>
<td>Faculty</td>
<td>Nothing to disclose</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Han, Summer</td>
<td>Faculty</td>
<td>Nothing to disclose</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Hand, Mary Ellen</td>
<td>Conference Planner (Chair, Program Committee)</td>
<td>1) CEC Oncology (CME non promotional)</td>
<td>1) Advisory Board</td>
</tr>
<tr>
<td></td>
<td>Abstract Reviewer</td>
<td>2) AstraZeneca</td>
<td>2) Contracted/Supported Research Grant</td>
</tr>
<tr>
<td>Harms, Christine</td>
<td>Faculty</td>
<td>1) ASCOvalence</td>
<td>3) Contracted/Supported Research Grant/Clinical Trial Support</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2) Abbvie</td>
<td>4) Contracted/Supported Research Grant/Clinical Trial Support</td>
</tr>
<tr>
<td></td>
<td></td>
<td>3) BMS</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>4) Amgen</td>
<td></td>
</tr>
<tr>
<td>Hann, Nasser</td>
<td>Conference Planner (Chair, Program Committee)</td>
<td>1) Served on the DSMAB for a study sponsored by “Beyond Spring.”</td>
<td>1) Consultant</td>
</tr>
<tr>
<td></td>
<td>Abstract Reviewer</td>
<td>2) Bristol-Myers Squibb, Genentech, AstraZeneca, Merck</td>
<td>1) Contracted/Supported Research Grant</td>
</tr>
<tr>
<td></td>
<td>Faculty</td>
<td>3) Royalties from serving as an editor to “Up to Date”</td>
<td>3) Royalties/Intellectual Property/Patent Holder</td>
</tr>
<tr>
<td>Harpole, David</td>
<td>Faculty</td>
<td>1) AstraZeneca</td>
<td>4) Contracted/Supported Research Grant</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2) AstraZeneca, Medtronic</td>
<td></td>
</tr>
<tr>
<td>Hassan, Raffi</td>
<td>Conference Planner (Chair, Program Committee)</td>
<td>1) Bayer, Morphotek, Aduro and TCR2 for conduct of clinical trials.</td>
<td>1) Research Grant</td>
</tr>
<tr>
<td></td>
<td>Abstract Reviewer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Harimag, Thomas</td>
<td>Conference Planner (Chair, Program Committee)</td>
<td>Nothing to disclose</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Name of Individual</td>
<td>Individual's Role(s) in Activity</td>
<td>Name of Commercial Interest(s)</td>
<td>Nature of Relationship(s)</td>
</tr>
<tr>
<td>-------------------</td>
<td>---------------------------------</td>
<td>-------------------------------</td>
<td>--------------------------</td>
</tr>
<tr>
<td>Higgins, Kristin</td>
<td>Faculty</td>
<td>1) Astra Zeneca</td>
<td>1) Advisory Board</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2) Astra Zeneca</td>
<td>2) Consultant</td>
</tr>
<tr>
<td>Ito, Kristin</td>
<td>Staff Liaison</td>
<td>Nothing to disclose</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Jafri, Shadia</td>
<td>Faculty</td>
<td>1) AstraZeneca, Tesaro and Alices</td>
<td>1) Research Funding</td>
</tr>
<tr>
<td>Kavanagh, Brian</td>
<td>Faculty</td>
<td>Nothing to disclose</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Kayne, Benjamin</td>
<td>Staff Liaison</td>
<td>Nothing to disclose</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Kelly, Karen</td>
<td>Faculty</td>
<td>1) AbbVie, AstraZeneca, EMD Serono, Inivata, Novartis, Regeneron, Symphogen</td>
<td>1) Advisory Board</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2) Data Monitoring Committee, AstraZeneca</td>
<td>2) Consultant</td>
</tr>
<tr>
<td></td>
<td></td>
<td>3) AbbVie, EMD Serono, Genentech, Regeneron</td>
<td>3) Contracted/Support Research Grant</td>
</tr>
<tr>
<td></td>
<td></td>
<td>4) UpToDate</td>
<td>4) Royalty/Intellectual Property/Patent Holder</td>
</tr>
<tr>
<td></td>
<td></td>
<td>5) Merk, Educational Lectures</td>
<td>5) Speaker</td>
</tr>
<tr>
<td>Kruser, Tim</td>
<td>Conference Planner (Chair, Program Committee)</td>
<td>1) AstraZeneca</td>
<td>1) Speaker Bureau</td>
</tr>
<tr>
<td></td>
<td>Abstract Reviewer</td>
<td>2) AstraZeneca</td>
<td>2) Advisory Board</td>
</tr>
<tr>
<td></td>
<td>Faculty</td>
<td>3) Oncive</td>
<td>3) Honorarium received from promotional activities</td>
</tr>
<tr>
<td>Laddi, Bonnie</td>
<td>Conference Planner (Chair, Program Committee)</td>
<td>1) AstraZeneca</td>
<td>1) Advisory Board</td>
</tr>
<tr>
<td></td>
<td>Abstract Reviewer</td>
<td>2) AstraZeneca</td>
<td>2) Consultant</td>
</tr>
<tr>
<td></td>
<td>Faculty</td>
<td>3) Nothing to disclose</td>
<td>3) Nothing to disclose</td>
</tr>
<tr>
<td>Land, Stephanie</td>
<td>Faculty</td>
<td>Nothing to disclose</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Last, Tociana</td>
<td>Conference Planner (Chair, Program Committee)</td>
<td>1) Merck, Takeda, AstraZeneca, Novartis, AbbVie, BMS, EMD Serono, Blueprint, Inivita, PharmaMar</td>
<td>1) Advisory Board</td>
</tr>
<tr>
<td></td>
<td>Abstract Reviewer</td>
<td>2) Nonscore</td>
<td>2) Steering Committee LUNAR</td>
</tr>
<tr>
<td></td>
<td>Faculty</td>
<td>3) Mirati</td>
<td>3) Steering Committee SAPPHIRE</td>
</tr>
<tr>
<td>Lee, Alan</td>
<td>Staff Liaison</td>
<td>Nothing to disclose</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Lindsey, Sara</td>
<td>Staff Liaison</td>
<td>Nothing to disclose</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Luske, Alexander</td>
<td>Faculty</td>
<td>1) AstraZeneca, RepliKiss, Varian Medical Systems Inc.</td>
<td>1) Speaker Bureau</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2) AstraZeneca</td>
<td>2) Advisory Board</td>
</tr>
<tr>
<td></td>
<td></td>
<td>3) Nothing to disclose</td>
<td>3) Honorarium received from promotional activities</td>
</tr>
<tr>
<td>Maher, Katie</td>
<td>Staff Liaison</td>
<td>Nothing to disclose</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Marmarelis, Melina</td>
<td>Faculty</td>
<td>1) AstraZeneca</td>
<td>1) Contracted/Support Research Grant</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2) Merck</td>
<td>2) Ownership/Stock Interest</td>
</tr>
<tr>
<td>Martin, Linda</td>
<td>Conference Planner (Chair, Program Committee)</td>
<td>1) AstraZeneca</td>
<td>1) Consultant</td>
</tr>
<tr>
<td></td>
<td>Abstract Reviewer</td>
<td>2) Paccia Pharmaceuticals</td>
<td>2) Advisory Board</td>
</tr>
<tr>
<td></td>
<td>Faculty</td>
<td>3) On Target Laboratories</td>
<td>3) Advisory Board (Steering committee for ELUCIDATE trial)</td>
</tr>
<tr>
<td>Mazieres, Julien</td>
<td>Faculty</td>
<td>1) Roche, BMS, MSD, AstraZeneca, Pfizer, Novartis</td>
<td>1) Advisory board</td>
</tr>
<tr>
<td>McCall, Neal</td>
<td>Faculty</td>
<td>Nothing to disclose</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Medlar, Anne</td>
<td>Faculty</td>
<td>Nothing to disclose</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Meiko, Dave</td>
<td>Staff Liaison</td>
<td>Nothing to disclose</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Metzger, Abigail</td>
<td>Staff Liaison</td>
<td>Nothing to disclose</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Mikhrida, Panchu</td>
<td>CME Committee Reviewer</td>
<td>Nothing to disclose</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Mulshine, James</td>
<td>Conference Planner (Chair, Program Committee)</td>
<td>1) AstraZeneca, Genentech/Roche, Exelixis, Jounce Therapeutics, Takeda Pharmaceuticals, Eli Lilly and Company, Calithera Biosciences, Amgen, lowance Biotherapeutics</td>
<td>1) Consulting or Advisory Role</td>
</tr>
<tr>
<td></td>
<td>Abstract Reviewer</td>
<td>2) Genentech/Roche, Merck, Novartis, Boehringer Ingelheim, Exelixis, Nektar Therapeutics, Takeda Pharmaceuticals, Adaptimmune, GSK</td>
<td>2) Contracted/Support Research Grant (to Institution)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>3) Nothing to disclose</td>
<td>3) Royalties</td>
</tr>
<tr>
<td></td>
<td></td>
<td>4) Nothing to disclose</td>
<td>4) Honoraoria</td>
</tr>
<tr>
<td>Neal, Joel</td>
<td>Faculty</td>
<td>Nothing to disclose</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Sittel, Kurt</td>
<td>Conference Planner (Chair, Program Committee)</td>
<td>1) AstraZeneca, Genentech/Roche, Exelixis, Jounce Therapeutics, Takeda Pharmaceuticals, Eli Lilly and Company, Calithera Biosciences, Amgen, lowance Biotherapeutics</td>
<td>1) Consulting or Advisory Role</td>
</tr>
<tr>
<td></td>
<td>Abstract Reviewer</td>
<td>2) Genentech/Roche, Merck, Novartis, Boehringer Ingelheim, Exelixis, Nektar Therapeutics, Takeda Pharmaceuticals, Adaptimmune, GSK</td>
<td>2) Contracted/Support Research Grant (to Institution)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>3) Nothing to disclose</td>
<td>3) Royalties</td>
</tr>
<tr>
<td></td>
<td></td>
<td>4) Nothing to disclose</td>
<td>4) Honoraoria</td>
</tr>
<tr>
<td></td>
<td></td>
<td>5) Nothing to disclose</td>
<td>5) Nothing to disclose</td>
</tr>
<tr>
<td>Name of Individual</td>
<td>Individual's Role(s) in Activity</td>
<td>Name of Commercial Interest(s)</td>
<td>Nature of Relationship(s)</td>
</tr>
<tr>
<td>--------------------</td>
<td>---------------------------------</td>
<td>---------------------------------</td>
<td>---------------------------</td>
</tr>
<tr>
<td>Owonikoko, Taofeek</td>
<td>Conference Planner (Chair, Program Committee) Abstract Reviewer Faculty</td>
<td>1) Novartis, Celgene, Lilly, Sandion, AbbVie, Eisai, G1 Therapeutics, Takeda, Seattle Genetics, Bristol-Myers Squibb, MedImmune, BerGenBio, Lilly, Amgen, AstraZeneca, PhamarMax, Boehringer Ingelheim, EMD Serono, XGxvers, Bayer, Heron Pharmaceuticals, ARMO Biosciences, Merck, Bayer, Jazz 2) Cambum 3) Novartis, Astellas Pharma, Bayer, StemCentrx, Regeneron, AstraZeneca/MedImmune, Abbie, G1 Therapeutics, Bristol-Myers, Canvus Pharmaceuticals, United Therapeutics, Amgen, Loxo/Lilly, Fujifilm, Pfizer, AngiA Neotheapetics, Incyte, Merck, Menarini, Turning Point, Orencia</td>
<td>1) Advisory Board 2) Ownership/Stock Interest 3) Contracted Supported Research Grant</td>
</tr>
<tr>
<td>Patel, At</td>
<td>Faculty</td>
<td>Nothing to disclose</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Patel, Jyoti</td>
<td>Faculty</td>
<td>1) AbbVie 2) AstraZeneca 3) BMS</td>
<td>1) Advisor 2) Advisor 3) Clinical Trial Support</td>
</tr>
<tr>
<td>Pavlova, Nick</td>
<td>CME Committee Reviewer</td>
<td>1) Bristol-Myers Squibb, MSID, Merck-Kga, Boehringer Ingelheim, Astra Zenea, Roche, Bayer, Novartis, Merck-Serono, Pfizer, Takeda, Ipsen 2) Pfizer, Takeda 3) Bayer, Pfizer, Roche</td>
<td>1) Advisory Board 2) Consultant 3) Institution: Contracted/Supported Research Grant</td>
</tr>
<tr>
<td>Pere-Morales, Jazmin</td>
<td>Faculty</td>
<td>Nothing to disclose</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Pettifor, Laura</td>
<td>Faculty</td>
<td>Nothing to disclose</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Pfurtschels, Zena</td>
<td>Faculty</td>
<td>1) Jazz Pharmaceuticals, G4 Therapeutics, InClyte, Eli Lilly, Medtronic 2) Novartis, Takeda, Spectrum, AstraZeneca, Tenaro, Cullinan</td>
<td>1) Advisory Board 2) Contracted/Supported Research Grant</td>
</tr>
<tr>
<td>Piatik, Debbie</td>
<td>Staff Liaison</td>
<td>Nothing to disclose</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Prent, Ann Marie</td>
<td>Staff Liaison</td>
<td>Nothing to disclose</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Rai, Manej</td>
<td>Faculty</td>
<td>Nothing to disclose</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Rahdan, Sawsan</td>
<td>Faculty</td>
<td>1) AstraZeneca 2) Amgen</td>
<td>1) Research Funding, Advisory Board 2) Lecture</td>
</tr>
<tr>
<td>Reyes, Monica</td>
<td>Faculty</td>
<td>Nothing to disclose</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Ricardi, Umberto</td>
<td>Conference Planner (Chair, Program Committee) Abstract Reviewer</td>
<td>Nothing to disclose</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Richemier, Kristin</td>
<td>Staff Liaison</td>
<td>Nothing to disclose</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Rimer, Andreas</td>
<td>Faculty</td>
<td>1) AstraZeneca, Varian Medical Systems, Merck, Cythera, MoreHealth 2) Philips/Dekta 3) AstraZeneca, Varian Medical Systems, Boehringer Ingelheim, Pfizer, Merck</td>
<td>1) Consultant 2) Travel Reimbursement 3) Research Grant</td>
</tr>
<tr>
<td>Rosenzweig, Ken</td>
<td>Faculty</td>
<td>Nothing to disclose</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Rosenzweig, Kenneth</td>
<td>Conference Planner (Chair, Program Committee) Abstract Reviewer</td>
<td>Nothing to disclose</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Rio, Upal Basu</td>
<td>Conference Planner (Chair, Program Committee) Abstract Reviewer</td>
<td>1) LUNAGenify Foundation</td>
<td>1) Consultant</td>
</tr>
<tr>
<td>Ryan, John</td>
<td>Faculty</td>
<td>Nothing to disclose</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Santana-Davila, Rafael</td>
<td>Faculty</td>
<td>1) Ariad, Genentech/Roche, Abbvie, PharmasMax, Bayer, BMS, Lilly, AstraZeneca 2) Lilly, Genentech, Abbvie, Bayer, BeyondSpring Pharmaceuticals, AstraZeneca (all institution)</td>
<td>1) Consulting/Advisory Role 2) Contracted/Support Research Grant</td>
</tr>
<tr>
<td>Scheunemann, Gritt</td>
<td>Staff Liaison</td>
<td>Nothing to disclose</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Seder, Christopher</td>
<td>Conference Planner (Chair, Program Committee) Abstract Reviewer</td>
<td>Nothing to disclose</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Sesh, Aubrey</td>
<td>Staff Liaison</td>
<td>Nothing to disclose</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Shell, Lynette</td>
<td>Conference Planner (Chair, Program Committee) Abstract Reviewer</td>
<td>1) EMD Serono 2) Institutional Research Funding (Roche/Genentech)</td>
<td>1) Consultant 2) Other</td>
</tr>
<tr>
<td>Shell, Lynette</td>
<td>Faculty</td>
<td>1) LGRO Oncology 2) AstraZeneca 3) Roche/Genentech</td>
<td>1) Advisory Board 2) Honorarium received from promotional activities 3) Contracted/Support Research Grant</td>
</tr>
<tr>
<td>Sierawski, Frank</td>
<td>Faculty</td>
<td>Nothing to disclose</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Shrewsberry, Kimberly</td>
<td>Conference Planner (Chair, Program Committee) Abstract Reviewer</td>
<td>Nothing to disclose</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Sivertsen, Kimberly</td>
<td>Faculty</td>
<td>Nothing to disclose</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Steliga, Matthew</td>
<td>Faculty</td>
<td>Nothing to disclose</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Steliga, Matthew</td>
<td>Conference Planner (Chair, Program Committee) Abstract Reviewer</td>
<td>Nothing to disclose</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Name of Individual</td>
<td>Individual’s Role(s) in Activity</td>
<td>Name of Commercial Interest(s)</td>
<td>Nature of Relationship(s)</td>
</tr>
<tr>
<td>-------------------</td>
<td>---------------------------------</td>
<td>--------------------------------</td>
<td>---------------------------</td>
</tr>
<tr>
<td>Stensgaard, Jeanette</td>
<td>Staff Liaison</td>
<td>Nothing to disclose</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Stiles, Brendan</td>
<td>Faculty</td>
<td>1) Gala Therapeutics, Chair of the Board of Directors for the Lung Cancer Research Foundation 2) Pfizer 3) AstraZeneca, Novartis, Medtronic, WebMD 4) PPO, LLC (Spouse)</td>
<td>1) Advisory Board 2) Ownership or Stock Interest 3) Consulting Fees/Honoraria 4) Salary/Ownership (Spouse)</td>
</tr>
<tr>
<td>Tanner, Nichole</td>
<td>Faculty</td>
<td>1) Exact Sciences, Oncomune, Oncoocyte 2) Olympia America</td>
<td>1) Grant Funding, Consulting 2) Consulting</td>
</tr>
<tr>
<td>Todd, Mary</td>
<td>Staff Liaison</td>
<td>Nothing to disclose</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Tong, Betty</td>
<td>Faculty</td>
<td>1) Medtronic, Inc. 2) Integra Life Sciences, Inc. 3) Tis隽m</td>
<td>1) Consultant 2) Speakers’ Bureau, Consultant (Spouse) 3) Consultant (Spouse)</td>
</tr>
<tr>
<td>Vainio, Everett</td>
<td>Conference Planners (Chair, Program Committee) 1) Abstract Reviewer 2) Faculty</td>
<td>1) AbbVie, Amgen, AstraZeneca, BMS, Celgene, Eli Lilly, EMD Serono, GenterTech, Genzyme, GlaxoSmithKline, Merck, Novartis, Regeneron 2) AbbVie, Amgen, AstraZeneca, BMS, Celgene, Eli Lilly, EMD Serono, Genentech, GlaxoSmithKline, Merck, Novartis, Regeneron 3) Takeda, Radius Health and Ascendis Pharma</td>
<td>1) Advisory Board 2) Consultant 3) Honorarium Received from Promotional Activities (Spouse)</td>
</tr>
<tr>
<td>Wakelee, Heather</td>
<td>Conference Planner (Chair, Program Committee) 1) Abstract Reviewer 2) Faculty</td>
<td>1) Daichi Sankyo, INC, Helixon, and Mirati NOT COMPENSATED: Callaworks, Genetech/Roche, and Merck 2) Research to practice 3) ACGA Biosciences, AstraZeneca/Immunomedics, Xcخرى, Celgene, Clovis Oncology, Genentech/Roche, Arroyo Therapeutics, Novartis, and Merck</td>
<td>1) Advisory Board 2) Consultant 3) Contracted/Supported Research Grant</td>
</tr>
<tr>
<td>Wang, Je</td>
<td>Faculty</td>
<td>Nothing to disclose</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Wistuba, Ignacio</td>
<td>Conference Planner (Chair, Program Committee) 1) Abstract Reviewer 2) Faculty</td>
<td>1) Genentech/Roche, Pfizer 2) Genentech/Roche, Bayer, Bristol-Myers Squibb, AstraZeneca/Immunomedics, Pfizer 3) HTG Molecular, AstraZeneca, Merck, GlaxoSmithKline, Guardant Health and MSD. 4) GeneTech, Oncoplex, HTG Molecular, DepCarex, Merck, Bristol-Myers Squibb, Medimmune, Adaptex, Adaptimmune, EMD Serono, Pfizer, Takeda, Amgen, Karius, Johnson &amp; Johnson, Bayer, Invacare, 4D, Novartis, Oncocyte and Alkayo.</td>
<td>1) Speakers Bureau 2) Advisory Board 3) Contracted/Supported Research Grant</td>
</tr>
<tr>
<td>Wood, Kelsey</td>
<td>Staff Liaison</td>
<td>Nothing to disclose</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Wynes, Murry</td>
<td>Staff Liaison</td>
<td>Nothing to disclose</td>
<td>Nothing to disclose</td>
</tr>
<tr>
<td>Yap, Timothy</td>
<td>Faculty</td>
<td>1) Artios, AstraZeneca, Bayer, Clovis, Constellation, Cypher, Eli Lilly, EMD Serono, Forbush, F-Star, GlaxoSmithKline, Genentech, ImmuneSensor, iQuam, Jounce, Karyopharm, Kyowa, Merck, Novartis, Pfizer, Ribbon Therapeutics, Regeneron, Repare, Sanofi, Scholar Rock, Seattle Genetics, Tesaro, and Vertex Pharmaceuticals 2) Altma, Aduro, AstraZeneca, Atalix, Axon, Bayer, Bristol Myers Squibb, Calithera, Clovis, Cyrenex, EMD Serono, F-Star, Guidepoint, Igyra, I-Mab, Janssen, Merck, Pfizer, Repare, Roche, Rubus, Schrodinger, Seattle Genetics, Varian and Zai Labs</td>
<td>1) Contracted/Supported Research Grant 2) Consultant</td>
</tr>
</tbody>
</table>